13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • IGNITE

    Acronym: 

    IGNITE

    ACTRN/NCT /ethics: 

    ACTRN12619001185156

    Scientific title: 

    Adavosertib targeting Cyclin E1 altered high grade serous ovarian cancer (HGSC) | IGNITE

    Summary of trial and patient characteristics

    Cancer Type Gynaecological
    Trial Type Treatment
    Phase Phase II Tumour Stream Ovarian Cancer
    Age Range 18 years and older Cancer Stage All stages
    Sex Female Anticipated Start Date 2020-03-01
    Molecular Target Anticipated End Date 2023-03-01
    Cancer Type Gynaecological
    Trial Type Treatment
    Phase Phase II
    Age Range 18 years and older
    Sex Female
    Molecular Target
    Tumour Stream Ovarian Cancer
    Cancer Stage All stages
    Anticipated Start Date 2020-03-01
    Anticipated End Date 2023-03-01

    Trial Summary

    IGNITE a phase II signal seeking trial of adavosertib (AZD1775) targeting recurrent high grade serous ovarian cancer (HGSC) with cyclin E1 (CCNE 1) over expression with and without gene amplification

    Lay Summary

    Adavosertib targeting Cyclin E1 altered high grade serous ovarian cancer (HGSC) | IGNITE

    Sponsor / Cooperative group

    ANZGOG

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Dr Ganessan Kichenadasse Not Yet Recruiting